Evolution of fit-for-purpose biomarker validations: An LBA perspective

5Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Biomarker ligand-binding assays need to be validated for use on clinical studies in the drug development process. There is not one single guidance to cover all types of biomarker assays and their intended uses. Therefore, it is up to the scientist to piece together a validation strategy based on published papers and other sources. Shown here is a summary of what to take into consideration during a validation and how to apply it for use in the drug development process.

Cite

CITATION STYLE

APA

Neely, R. J. (2018, June 1). Evolution of fit-for-purpose biomarker validations: An LBA perspective. Bioanalysis. Future Medicine Ltd. https://doi.org/10.4155/bio-2017-0267

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free